All News
Filter News
Found 809,049 articles
-
The U.S. Justice Department announced yesterday that it will not challenge the merger of CVS Health Corp and health insurer Aetna.
-
Novartis and Michael Cohen, attorney to President Donald Trump, had a much deeper relationship than has been previously disclosed and was selling access to the White House, a new report issued by Senate Democrats alleges.
-
President Trump was able to declare a small victory in the arena of drug pricing earlier this week when Pfizer opted to delay its second price-hike of the year. Other companies though have not followed suit and have gone through with price increases for their drugs.
-
Amgen and UCB resubmitted their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Evenity (romosozumab).
-
Saturnino “Nino” Fanlo, chief financial officer and chief operations officer of Human Longevity (HLI), has left the company. Fanlo was implicated in a scandal at his previous employer, online lender Social Finance (SoFi).
-
In a particularly large result, a St. Louis jury awarded almost $4.7 billion in total damages to 22 women and their families in a lawsuit against Johnson & Johnson.
-
In March venture capital firm ShangPharma Innovations announced its plans to expand its life sciences incubator in San Francisco by 40 percent, including state-of-the-art laboratory infrastructure upgrades to its facility. That investment is paying off as the incubator is growing.
-
Verily will team up with San Diego-based ResMed, a company that specializes in the treatment of sleep disorders, to launch a new joint business venture to address sleep apnea and other sleeping disorders.
-
July 13 Research Roundup: Gene Therapy for Cholesterol, Beta-Thalassemia, and Kidney Disease, and...
7/13/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them from gene therapy for cholesterol to kidney disease and more. -
Shares of Advaxis are skyrocketing this morning after the company announced the U.S. Food and Drug Administration lifted the clinical hold on its Investigational New Drug Application for a Phase I/II cancer study.
-
Didier Miraton joins CardioRenal’s supervisory board
7/13/2018
Didier Miraton joins CardioRenal’s supervisory board Former CEO of Michelin and Pierre Fabre brings industry knowledge to telemedicine start-up, to assist in scaling up manufacturing capacities of its monitoring device for patients with severe heart failure
-
FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity
7/13/2018
The U.S. Food and Drug Administration (FDA) is alerting health care professionals and patients of a voluntary recall of several drug products containing the active ingredient valsartan, used to treat high blood pressure and heart failure.
-
Yposkesi appoints Dr. Fraser Wright as senior advisor
7/13/2018
With extensive experience in gene therapy vector manufacturing, Dr. Wright, scientific co-founder and former CTO of Spark Therapeutics, will support Yposkesi’s innovation in viral vector design, production and characterization
-
Citius Announces Key Addition to its Scientific Advisory Board
7/13/2018
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that Dr. Lawrence Mermel has accepted a position on the Citius Scientific Advisory Board.
-
FDA approves the first drug with an indication for treatment of smallpox
7/13/2018
The U.S. Food and Drug Administration today approved TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox.
-
--U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)--
7/13/2018
First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC.
-
Kypha Acquires Biosensia - Expands First-in-Class Immune Status Monitoring Platforms
7/13/2018
Kypha has acquired Biosensia
-
Survey Focuses on Hospital System and Private Equity Investments in Physician Practices
7/13/2018
Clinic Service announced it is surveying medical practices to learn about their experiences with, and attitudes toward, the purchase of medical practices by hospital systems and private equity funds.
-
Statement on event sponsorship and other promotional activities by federally licensed producers of cannabis
7/13/2018
Health Canada is concerned by the decision of some federally licensed producers of cannabis for medical purposes to sponsor events, such as music festivals, and engage in other promotional activities, as reported recently by several Canadian media outlets.
-
Rev. Fr. Emmanuel Lemelson Calls on Congress, Office of Inspector General to Investigate SEC Failures
7/13/2018
Failure to prosecute Alleged Multi-Year Accounting and Securities Fraud at Ligand Pharmaceuticals (NASDAQ: LGND) Diminishes SEC Credibility, Warrants Investigation